Background and Purpose Both cerebral hypoperfusion and vascular risk factors have been implicated in early aging of the brain and the development of neurodegenerative disease. However, the current knowledge of the importance of cardiovascular health on resting brain perfusion is limited. The aim of the present study was to elucidate the relation between brain perfusion variability and risk factors of endothelial dysfunction and atherosclerosis in healthy aged subjects. Methods Thirty-eight healthy subjects aged 50–75 years old were included. Mean global brain perfusion was measured using magnetic resonance phase contrast mapping and regional brain perfusion by use of arterial spin labeling. Results Mean global brain perfusion was inversely correlated with caffeine and hematocrit, and positively with end-tidal PCO2. Furthermore, the mean global brain perfusion was inversely correlated with circulating homocysteine, but not with asymmetric dimethylarginine, dyslipidemia or the carotid intima-media thickness. The relative regional brain perfusion was associated with circulating homocysteine, with a relative parietal hypoperfusion and a frontal hyperperfusion. No effect on regional brain perfusion was observed for any of the other risk factors. A multiple regression model including homocysteine, caffeine, hematocrit and end-tidal PCO2, explained nearly half of the observed variability. Conclusion Both intrinsic and extrinsic factors influenced global cerebral perfusion variation between subjects. Further, the results suggest that the inverse relation between homocysteine and brain perfusion is owing to other mechanisms, than reflected by asymmetric dimethylarginine, and that homocysteine may be a marker of cerebral perfusion in aging brains.
References
[1]
de la Torre JC (2012) Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer's disease. J Alzheimers Dis 32: 553–567.
[2]
Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Vrooman HA, et al. (2008) Total cerebral blood flow and total brain perfusion in the general population: the Rotterdam Scan Study. J Cereb Blood Flow Metab 28: 412–419. doi: 10.1038/sj.jcbfm.9600526
[3]
Cohen RA, Poppas A, Forman DE, Hoth KF, Haley AP, et al. (2009) Vascular and cognitive functions associated with cardiovascular disease in the elderly. J Clin Exp Neuropsychol 31: 96–110. doi: 10.1080/13803390802014594
[4]
Henriksen OM, Larsson HB, Hansen AE, Gruner JM, Law I, et al. (2012) Estimation of intersubject variability of cerebral blood flow measurements using MRI and positron emission tomography. J Magn Reson Imaging 35: 1290–1299. doi: 10.1002/jmri.23579
[5]
Pase MP, Grima NA, Stough CK, Scholey A, Pipingas A (2012) Cardiovascular disease risk and cerebral blood flow velocity. Stroke 43: 2803–2805. doi: 10.1161/strokeaha.112.666727
[6]
Jennings JR, Heim AF, Kuan DC, Gianaros PJ, Muldoon MF, et al. (2013) Use of total cerebral blood flow as an imaging biomarker of known cardiovascular risks. Stroke 44: 2480–2485. doi: 10.1161/strokeaha.113.001716
[7]
Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, et al. (2008) Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 65: 642–649. doi: 10.1001/archneur.65.5.642
[8]
The Homocysteine Study Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015–2022. doi: 10.1001/jama.288.16.2015
[9]
Wald DS, Kasturiratne A, Simmonds M (2011) Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement 7: 412–417. doi: 10.1016/j.jalz.2010.08.234
[10]
Blackwell S (2010) The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 47: 17–28. doi: 10.1258/acb.2009.009196
[11]
Notsu Y, Nabika T, Bokura H, Suyama Y, Kobayashi S, et al. (2009) Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am J Hypertens 22: 257–262.
[12]
Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR (2009) Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 40: 3180–3185. doi: 10.1161/strokeaha.109.557280
[13]
Sojkova J, Najjar SS, Beason-Held LL, Metter EJ, Davatzikos C, et al. (2010) Intima-media thickness and regional cerebral blood flow in older adults. Stroke 41: 273–279. doi: 10.1161/strokeaha.109.566810
[14]
Rubba P, Faccenda F, Di SS, Gnasso A, Scarpato N, et al. (1993) Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke 24: 1154–1161. doi: 10.1161/01.str.24.8.1154
[15]
Ayata C, Shin HK, Dilekoz E, Atochin DN, Kashiwagi S, et al. (2013) Hyperlipidemia disrupts cerebrovascular reflexes and worsens ischemic perfusion defect. J Cereb Blood Flow Metab.
[16]
Henriksen OM, Jensen LT, Krabbe K, Larsson HB, Rostrup E (2013) Relationship between cardiac function and resting cerebral blood flow: MRI measurements in healthy elderly subjects. Clin Physiol Funct Imaging: In press.
[17]
Petersen ET, Lim T, Golay X (2006) Model-free arterial spin labeling quantification approach for perfusion MRI. Magn Reson Med 55: 219–232. doi: 10.1002/mrm.20784
[18]
Chappell MA, Woolrich MW, Petersen ET, Golay X, Payne SJ (2013) Comparing model-based and model-free analysis methods for QUASAR arterial spin labeling perfusion quantification. Magn Reson Med 69: 1466–1475. doi: 10.1002/mrm.24372
[19]
Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, et al. (2005) Impact of age-related cerebral white matter changes on the transition to disability — the LADIS study: rationale, design and methodology. Neuroepidemiology 24: 51–62. doi: 10.1159/000081050
[20]
de Jong S, Teerlink T (2006) Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 353: 287–289. doi: 10.1016/j.ab.2006.03.010
[21]
Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA (2002) Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303: 131–137. doi: 10.1006/abio.2001.5575
[22]
Norager CB, Jensen MB, Weimann A, Madsen MR (2006) Metabolic effects of caffeine ingestion and physical work in 75-year old citizens. A randomized, double-blind, placebo-controlled, cross-over study. Clin Endocrinol (Oxf) 65: 223–228. doi: 10.1111/j.1365-2265.2006.02579.x
[23]
D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743–753. doi: 10.1161/circulationaha.107.699579
[24]
Cacciapuoti F (2011) Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 32: 82–88. doi: 10.1007/s11239-011-0550-4
[25]
Wang X, Qin X, Demirtas H, Li J, Mao G, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369: 1876–1882. doi: 10.1016/s0140-6736(07)60854-x
[26]
Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, et al. (2013) Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110: 9523–9528. doi: 10.1073/pnas.1301816110
[27]
Zhang F, Slungaard A, Vercellotti GM, Iadecola C (1998) Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol 274: R1704–R1711.
[28]
Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, et al. (2003) Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108: 933–938. doi: 10.1161/01.cir.0000085067.55901.89
[29]
Demuth K, Drunat S, Girerd X, Moatti N, Paul JL, et al. (2002) Homocysteine is the only plasma thiol associated with carotid artery remodeling. Atherosclerosis 165: 167–174. doi: 10.1016/s0021-9150(02)00205-8
[30]
Lim MH, Cho YI, Jeong SK (2009) Homocysteine and pulsatility index of cerebral arteries. Stroke 40: 3216–3220. doi: 10.1161/strokeaha.109.558403
[31]
Nilsson K, Warkentin S, Hultberg B, Faldt R, Gustafson L (2000) Treatment of cobalamin deficiency in dementia, evaluated clinically and with cerebral blood flow measurements. Aging (Milano ) 12: 199–207. doi: 10.1007/bf03339837
[32]
Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM (2010) APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol 67: 93–98. doi: 10.1001/archneurol.2009.913
[33]
Cherbuin N, Leach LS, Christensen H, Anstey KJ (2007) Neuroimaging and APOE genotype: a systematic qualitative review. Dement Geriatr Cogn Disord 24: 348–362. doi: 10.1159/000109150
[34]
Ostergaard L, Aamand R, Gutierrez-Jimenez E, Ho YC, Blicher JU, et al. (2013) The capillary dysfunction hypothesis of Alzheimer's disease. Neurobiol Aging 34: 1018–1031. doi: 10.1016/j.neurobiolaging.2012.09.011
[35]
Rocha MS, Teerlink T, Janssen MC, Kluijtmans LA, Smulders Y, et al. (2012) Asymmetric dimethylarginine in adults with cystathionine beta-synthase deficiency. Atherosclerosis 222: 509–511. doi: 10.1016/j.atherosclerosis.2012.03.009
[36]
ten Dam VH, Box FM, de Craen AJ, van den Heuvel DM, Bollen EL, et al. (2005) Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in elderly at risk for vascular disease. Stroke 36: 1633–1636. doi: 10.1161/01.str.0000173162.88600.29
[37]
Henriksen OM, Kruuse C, Olesen J, Jensen LT, Larsson HB, et al. (2013) Sources of variability of resting cerebral blood flow in healthy subjects: a study using 133Xe SPECT measurements. J Cereb Blood Flow Metab 33: 787–792. doi: 10.1038/jcbfm.2013.17
[38]
Tang C, Blatter DD, Parker DL (1993) Accuracy of phase-contrast flow measurements in the presence of partial-volume effects. J Magn Reson Imaging 3: 377–385. doi: 10.1002/jmri.1880030213
[39]
Eskelinen MH, Kivipelto M (2010) Caffeine as a protective factor in dementia and Alzheimer's disease. J Alzheimers Dis 20 Suppl 1S167–S174.
